Trial ID or NCT#

NCT02509156

Status

not recruiting iconNOT RECRUITING

Purpose

The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC). The secondary purpose of this study is to obtain preliminary evidence for therapeutic efficacy of allo-MSCs delivered by transendocardial injection to cancer survivors with LV dysfunction secondary to AIC.

Official Title

A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 79 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Phillip C. Yang, MD
Phillip C. Yang, MD
Cardiologist
Professor of Medicine (Cardiovascular Medicine)

Contact us to find out if this trial is right for you.

CONTACT

Fouzia Khan
(650) 736-1410